On September 1, 2021 Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, reported its participation in the following medical and investor conferences (Press release, Aeglea BioTherapeutics, SEP 1, 2021, View Source [SID1234587130]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor Meetings

2021 Wells Fargo Virtual Healthcare Conference, September 9
H.C. Wainwright 23rd Annual Global Investment Conference, September 13
2021 Cantor Virtual Global Healthcare Conference, September 27
Medical Conferences

International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2021), September 17 – 22
50th Child Neurology Society (CNS) Annual Meeting, September 29 – October 2
At both the MDS Virtual Congress and the CNS Annual Meeting, a poster presentation will outline a subset analysis from the Company’s previously reported Phase 1/2 and Phase 2 open label extension studies of pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D). In the poster, analysis of gait kinematics and spasticity was completed using video compilations.

To access live and/or archived Investor Conference webcasts, visit the Events & Presentations section of the Company’s website. A replay of Company webcasts is archived on the website for 30 days following presentations.